Table 3.
Results of multivariate analysis
| Variable | OS | PFS | RI | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | HR (95% CI) | P | |
| Age | NS | NS | ||||
| ≤ 55 | Reference | |||||
| ≥ 56 | 1.85 (1.28–2.68) | 0.001 | ||||
| Gender | ||||||
| Male | Reference | |||||
| Female | 0.57 (0.37–0.89) | 0.014 | ||||
| ISS stage | ||||||
| I | Reference | Reference | ||||
| II | 1.88 (1.12–3.15) | 0.018 | 1.22 (0.81–1.85) | 0.348 | ||
| III | 3.14 (1.77–5.59) | < 0.001 | 1.87 (1.16–3.02) | 0.010 | ||
| No. of prior therapy lines | NS | NS | ||||
| 1 | Reference | |||||
| ≥ 2 | 1.73 (1.22–2.46) | 0.002 | ||||
| Extramedullary disease | NS | |||||
| No | Reference | |||||
| Yes | 1.59 (1.13–2.26) | 0.009 | ||||
| Karnofsky performance status | ||||||
| ≥80 | Reference | |||||
| < 80 | 4.16 (2.49–6.95) | < 0.001 | ||||
| Conditioning regimen | NS | |||||
| MAC | Reference | |||||
| RIC | 3.85 (1.25–11.88) | 0.019 | ||||
| Therapy group | NS | |||||
| Upfront-allo | Reference | Reference | ||||
| Auto-allo | 0.25 (0.075–0.81) | 0.022 | 0.93 (0.60–1.46) | 0.758 | ||
| Relapse | 0.63 (0.20–1.99) | 0.432 | 2.25 (1.43–3.55) | < 0.001 | ||
| aGVHD ≥ gr.2 | NS | |||||
| Yes | Reference | Reference | ||||
| No | 0.27 (0.17–0.45) | < 0.001 | 0.42 (0.28–0.65) | < 0.001 | ||
| cGVHD | ||||||
| Yes | Reference | Reference | Reference | |||
| No | 2.62 (1.67–4.12) | < 0.001 | 2.30 (1.57–3.36) | < 0.001 | 1.61 (1.13–2.29) | 0.008 |
OS overall survival, PFS progression-free survival, RI relapse incidence, ISS International Staging System, MAC myeloablative conditioning, RIC reduced intensity conditioning, Upfront-allo allo-SCT performed first line without a previous auto-SCT, auto-allo allo-SCT performed after auto-SCT in first line, relapse allo-SCT performed after relapse, aGVHD acute graft-versus-host disease, cGVHD chronic graft-versus-host disease, NS not significant
Bold values indicate statistical significance at P < 0.05